← ANALYST RATINGS · TIPRANKS
Annexon Biosciences (ANNX): analyst forecast and price target
Analyst consensus
Moderate Buy6 Buy2 Hold1 Sell
Ratings of 9 analysts in the last 3 months12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $13.36, the highest $27.00, the lowest $3.00. The average is +291.7% from the last price of $3.41.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $3.50−12.5% | Hold | +2.6% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | +2.6% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $3.50−12.5% | Hold | +2.6% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.50−12.5% | Hold | +2.6% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | +2.6% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $3.50−12.5% | Hold | +2.6% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.50 → $4.00−11.1% | Hold | +17.3% | Reiterated | 13.10.26on TipRanks 06:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.50 → $4.00−11.1% | Hold | +17.3% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.50 → $4.00−11.1% | Hold | +17.3% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.50 → $4.00−11.1% | Hold | +17.3% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.50 → $4.00−11.1% | Hold | +17.3% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $4.50+12.5% | Hold | +32.0% | Reiterated | 01.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $4.50+12.5% | Hold | +32.0% | Reiterated | 01.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $4.50+12.5% | Hold | +32.0% | Reiterated | 01.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $4.50+12.5% | Hold | +32.0% | Reiterated | 01.10.26on TipRanks 05:05 | — | |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $14.00 → $15.00+7.1% | Buy | +339.9% | Assigned | 30.09.26on TipRanks 07:10 | +2.6%next day −2.8% · 5 days −7.1% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $4.00+14.3% | Hold | +17.3% | Reiterated | 29.09.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $4.00+14.3% | Hold | +17.3% | Reiterated | 29.09.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $4.00+14.3% | Hold | +17.3% | Reiterated | 29.09.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $4.00+14.3% | Hold | +17.3% | Reiterated | 29.09.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $4.50+12.5% | Hold | +32.0% | Reiterated | 29.09.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 | Hold | +17.3% | Reiterated | 29.09.26on TipRanks 05:05 | — | |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $8.00 | Buy | +134.6% | Reiterated | 28.09.26on TipRanks Sep 29 05:35 | +10.9%next day +3.2% · 5 days +3.5% | ↗ |
| Ananda Ghosh★★★★★★★★★★#1171 · hits 53% · avg +20.8% | H.C. Wainwright | $14.00 | Buy | +310.6% | Reiterated | 14.08.26on TipRanks Aug 13 08:26 | −2.0%next day +0.8% · 5 days +0.4% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $27.00 | Buy | +691.8% | Reiterated | 13.08.26on TipRanks 07:00 | −2.0%next day +0.8% · 5 days +0.4% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 12.08.26on TipRanks Aug 13 10:35 | −0.4%next day −2.0% · 5 days +3.6% | ↗ |
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | $25.00 | Buy | +633.1% | Reiterated | 12.08.26on TipRanks 11:55 | −0.4%next day −2.0% · 5 days +3.6% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $7.00 | Hold | +105.3% | Reiterated | 06.08.26on TipRanks Aug 7 14:05 | +4.4%next day −4.0% · 5 days −7.3% | ↗ |
| Unknown Analyst | Raymond James | $7.85 | Hold | +130.2% | Initiated | 21.07.26on TipRanks Sep 15 06:05 | −4.1%next day −2.9% · 5 days −6.8% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $3.00 | Sell | −12.0% | Initiated | 21.07.26on TipRanks Jul 24 05:09 | −4.1%next day −2.9% · 5 days −6.8% | ↗ |
| William Maughan★★★★★★★★★★#1398 · hits 46% · avg +16.2% | Clear Street | $17.00 | Buy | +398.5% | Reiterated | 30.03.26on TipRanks 19:50 | +8.8%next day −4.0% · 5 days +5.3% | ↗ |
| Daniil Gataulin★★★★★★★★★★#2392 · hits 39% · avg +14.9% | Chardan Capital | $16.00 | Buy | +369.2% | Initiated | 23.12.25on TipRanks 04:30 | −2.0%next day +1.0% · 5 days −0.9% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $10.00 | Buy | +193.3% | Reiterated | 11.11.25on TipRanks 09:55 | −0.6%next day −4.4% · 5 days +11.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Annexon Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $13.36 at a price of $4.23 (+215.8%); now: $13.36 at $3.41 (+291.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 5 | 8 | 13 | 16 | 10 |
| Buy | 5 | 2 | 2 | 1 | 1 | 1 |
| Hold | 1 | 1 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 1 | 1 | 1 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.28 (from $-0.30 to $-0.25). Last quarter: $-0.28.
Best top-analyst consensus in the sector · Healthcare
About Annexon Biosciences
- CEO: Douglas E. Love
- Employees: 92
- 1400 Sierra Point Parkway, Brisbane, CA, 94005, US
- www.annexonbio.com
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
Data from the stock’s TipRanks forecast page, read 81 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗